Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025951108> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W3025951108 endingPage "584" @default.
- W3025951108 startingPage "579" @default.
- W3025951108 abstract "Background Patients with metastatic and locally advanced bladder or prostate cancer may suffer from pelvic symptoms such as pain, obstruction, and hemorrhage. Local tumor growth is associated with significant morbidity and systemic therapy is often ineffective. Local therapies such as bladder irrigation, transurethral resection of the prostate, and fulguration of bleeding vessels provide relief but often require repeated treatments. Objectives The aim of this work was to review the current status of palliative pelvic radiotherapy for metastatic bladder and prostate cancer. Materials and methods The available literature was evaluated and treatment recommendations are proposed depending on different clinical scenarios. Results To date, no standard regimen exists for the delivery of palliative pelvic radiotherapy. Various radiotherapy schedules manage successful and long-term palliation of pelvic symptoms in most patients and result in acceptable toxicity. For bladder cancer, the most common dose and fractionation regimens range from 20 Gy in 5 fractions to 40 Gy in 20 fractions. Some retrospective studies evaluated 6 weekly fractions of 6 Gy to a total dose of 36 Gy. For prostate cancer, the most common dose and fractionation regimes range from 30 Gy in 10 fractions to 50 Gy in 25 fractions. The symptomatic response rate is between 70 and 95%. Conclusions Pelvic radiotherapy for patients with metastatic and locally advanced bladder or prostate cancer provides effective and long-term palliation of a variety of symptoms such as pain, obstruction, and hemorrhage, with acceptable toxicity. Future studies should investigate the optimal target dose and fractionation schedule." @default.
- W3025951108 created "2020-05-21" @default.
- W3025951108 creator A5011133286 @default.
- W3025951108 creator A5045352854 @default.
- W3025951108 creator A5052929326 @default.
- W3025951108 creator A5055480338 @default.
- W3025951108 creator A5061644837 @default.
- W3025951108 date "2017-05-01" @default.
- W3025951108 modified "2023-10-08" @default.
- W3025951108 title "When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen" @default.
- W3025951108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28349190" @default.
- W3025951108 hasPublicationYear "2017" @default.
- W3025951108 type Work @default.
- W3025951108 sameAs 3025951108 @default.
- W3025951108 citedByCount "0" @default.
- W3025951108 crossrefType "journal-article" @default.
- W3025951108 hasAuthorship W3025951108A5011133286 @default.
- W3025951108 hasAuthorship W3025951108A5045352854 @default.
- W3025951108 hasAuthorship W3025951108A5052929326 @default.
- W3025951108 hasAuthorship W3025951108A5055480338 @default.
- W3025951108 hasAuthorship W3025951108A5061644837 @default.
- W3025951108 hasConcept C121608353 @default.
- W3025951108 hasConcept C126322002 @default.
- W3025951108 hasConcept C126894567 @default.
- W3025951108 hasConcept C141071460 @default.
- W3025951108 hasConcept C2775908122 @default.
- W3025951108 hasConcept C2776235491 @default.
- W3025951108 hasConcept C2776537999 @default.
- W3025951108 hasConcept C2777416452 @default.
- W3025951108 hasConcept C2780192828 @default.
- W3025951108 hasConcept C2781413609 @default.
- W3025951108 hasConcept C509974204 @default.
- W3025951108 hasConcept C71924100 @default.
- W3025951108 hasConceptScore W3025951108C121608353 @default.
- W3025951108 hasConceptScore W3025951108C126322002 @default.
- W3025951108 hasConceptScore W3025951108C126894567 @default.
- W3025951108 hasConceptScore W3025951108C141071460 @default.
- W3025951108 hasConceptScore W3025951108C2775908122 @default.
- W3025951108 hasConceptScore W3025951108C2776235491 @default.
- W3025951108 hasConceptScore W3025951108C2776537999 @default.
- W3025951108 hasConceptScore W3025951108C2777416452 @default.
- W3025951108 hasConceptScore W3025951108C2780192828 @default.
- W3025951108 hasConceptScore W3025951108C2781413609 @default.
- W3025951108 hasConceptScore W3025951108C509974204 @default.
- W3025951108 hasConceptScore W3025951108C71924100 @default.
- W3025951108 hasIssue "5" @default.
- W3025951108 hasLocation W30259511081 @default.
- W3025951108 hasOpenAccess W3025951108 @default.
- W3025951108 hasPrimaryLocation W30259511081 @default.
- W3025951108 hasVolume "56" @default.
- W3025951108 isParatext "false" @default.
- W3025951108 isRetracted "false" @default.
- W3025951108 magId "3025951108" @default.
- W3025951108 workType "article" @default.